Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 3/20 | 0.34 |
| ▸ | PPARA | Q07869 | 3/20 | 0.34 |
| ▸ | PPARD | Q03181 | 2/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23723265 | 1.00 | APEX1 (0.48) | APEX1CYP1A2CYP2C9HPGDHSD17B10 | |
| SCHEMBL30633649 | 0.91 | RAB9A (0.38) | APEX1HPGDPOLBGAAMAPT | |
| SCHEMBL23723228 | 0.90 | L3MBTL1 (0.45) | APEX1POLBGAARAB9ALMNA | |
| SCHEMBL23723229 | 0.90 | L3MBTL1 (0.45) | APEX1POLBGAARAB9ALMNA | |
| SCHEMBL26758437 | 0.88 | IDO1 (0.41) | HSD17B10MAPTALDH1A1RAB9ALMNA | |
| SCHEMBL23745932 | 0.87 | NQO2 (0.41) | CYP1A2CYP2C9POLBGAAMAPT | |
| SCHEMBL23723242 | 0.87 | MAPT (0.43) | GAAMAPTALDH1A1RAB9ALMNA | |
| SCHEMBL23723241 | 0.87 | MAPT (0.43) | GAAMAPTALDH1A1RAB9ALMNA | |
| SCHEMBL23746020 | 0.86 | CTSK (0.35) | CYP1A2CYP2C9POLBGAAALDH1A1 | |
| SCHEMBL30633625 | 0.86 | CTSK (0.35) | CYP1A2CYP2C9POLBGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12578335-B2 | Bioprobes for lysyl oxidases and uses thereof | SYNTARA LIMITED (AU) | 2026-03-17 | — | — | US | disclosed |
| US-20230349907-A1 | BIOPROBES FOR LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2023-11-02 | — | — | US | disclosed |
| US-20230349907-A1 | BIOPROBES FOR LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2023-11-02 | — | — | US | disclosed |
| US-20230349907-A1 | BIOPROBES FOR LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2023-11-02 | — | — | US | disclosed |
| WO-2021155439-A1 | BIOPROBES FOR LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021155439-A1 | BIOPROBES FOR LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230349907-A1 | BIOPROBES FOR LYSYL OXIDASES AND USES THEREOF | MAOB, LOX, LPO | APEX1 298/4885CYP1A2 200/4885CYP2C9 383/4885 |
| US-12578335-B2 | Bioprobes for lysyl oxidases and uses thereof | LOXL1, LOX, LOXL2 | APEX1 1156/4885CYP1A2 525/4885CYP2C9 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.